Pressure Builds On Neulasta As EMA Accepts Biosimilar Filings
This article was originally published in Scrip
Executive Summary
Amgen's Neulasta (pegfilgrastim) is coming under increasing competitive pressure after the European Medicines Agency revealed that its scientific committee, the CHMP, has two biosimilar versions of the neutropenia drug under review.